ABVX analyst estimates
Abivax (ABVX) analyst ratings, the average price target and its range, and every firm's latest call.
ABVX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 22, 2026 | Truist Financial | Abivax price target lowered to $151 from $155 at Truist | $151.00 |
| Sep 22, 2026 | Wedbush | Abivax price target lowered to $118 from $140 at Wedbush | $118.00 |
| Sep 9, 2026 | Goldman Sachs | Abivax initiated with a Buy at Goldman Sachs | $155.00 |
| Jul 24, 2026 | Morgan Stanley | Abivax price target raised to $180 from $132 at Morgan Stanley | $180.00 |
| Jul 9, 2026 | Piper Sandler | Abivax price target raised to $175 from $165 at Piper Sandler | $175.00 |
| Jul 2, 2026 | Truist Financial | Abivax price target raised to $155 from $135 at Truist | $155.00 |
| Jun 30, 2026 | BTIG | Abivax (ABVX) PT Raised to $175 at BTIG | $175.00 |
| Jun 30, 2026 | Jefferies | Abivax upgraded to Buy from Hold at Jefferies | $158.00 |
| Jun 3, 2026 | Wolfe Research | Abivax price target lowered to $136 from $176 at Wolfe Research | $136.00 |
| Jun 2, 2026 | Jefferies | Jefferies Downgrades Abivax (ABVX) to Hold | $90.00 |
| Jun 2, 2026 | Wedbush | Wedbush upgrades Abivax to Neutral, lowers target to $90 | $90.00 |
| Jun 2, 2026 | Morgan Stanley | Abivax price target lowered to $132 from $145 at Morgan Stanley | $132.00 |
| Jun 2, 2026 | Truist Financial | Abivax price target lowered to $135 from $140 at Truist | $135.00 |
| Feb 24, 2026 | Wedbush | Abivax initiated with a Neutral at Wedbush | $110.00 |
| Jan 9, 2026 | Morgan Stanley | Abivax price target raised to $145 from $101 at Morgan Stanley | $145.00 |
- 5 firms rate ABVX: 5 buy, 0 hold, 0 sell.
- The average price target is $156.00 from 8 analysts, from $118.00 to $180.00.
Updated 2026-11-07 11:53 UTC